Abstract
Elevated levels of triglycerides are associated with pancreatitis and an increased risk of coronary heart disease. Numerous pharmacologic therapies are available to treat hypertriglyceridemia, including prescription omega-3 fatty acids, which reduce triglyceride levels by 20-50%. Available data indicate the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may be beneficial for secondary prevention of coronary heart disease. Products containing DHA may increase low-density lipoprotein cholesterol (LDL-C) and, subsequently, coronary heart disease risk. We reviewed prescription omega-3 fatty acid products, of which two-omega-3 acid ethyl esters (OM3EE) and omega-3 carboxylic acid (OM3CA)-contain both DHA and EPA, whereas the other-icosapent ethyl (IPE)-contains EPA only. We identified three retrospective chart reviews and three case reports comparing IPE with OM3EE, whereas two studies compared IPE with placebo. We also reviewed the major studies of OM3EE versus placebo used to gain US FDA approval. LDL-C levels decreased or did not increase significantly in all available studies and case reports in patients receiving the IPE product, with the best data supporting a dose of 4 g per day. The majority o...Continue Reading
References
Dec 29, 1998·Journal of Cardiovascular Risk·W S HarrisK Osmundsen
Apr 27, 1999·Atherosclerosis·H J PownallC M Ballantyne
May 9, 2000·The American Journal of Clinical Nutrition·T A MoriL J Beilin
Apr 29, 2004·The Journal of Nutrition·Tine TholstrupBrittmarie Sandström
Apr 3, 2007·Lancet·Mitsuhiro YokoyamaUNKNOWN Japan EPA lipid intervention study (JELIS) Investigators
Sep 11, 2007·Clinical Therapeutics·Michael H DavidsonUNKNOWN COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators
Sep 22, 2010·The American Journal of Cardiology·Jerome D CohenTerry A Jacobson
Apr 20, 2011·Circulation·Michael MillerUNKNOWN Council on the Kidney in Cardiovascular Disease
Jun 21, 2011·The American Journal of Cardiology·Harold E BaysParesh N Soni
Jan 24, 2012·Journal of Clinical Lipidology·Terry A JacobsonParesh N Soni
Jul 24, 2012·The American Journal of Cardiology·Christie M BallantyneParesh N Soni
Aug 21, 2012·Journal of Lipid Research·Donald B JumpSasmita Tripathy
Sep 4, 2013·Clinical Therapeutics·Kevin C MakiMichael H Davidson
Nov 14, 2013·Circulation·Neil J StoneUNKNOWN American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Feb 12, 2014·Clinical Medicine Insights. Cardiology·Daniel E Hilleman, Mark A Malesker
Feb 18, 2014·Journal of Clinical Lipidology·John J P KasteleinMichael H Davidson
Jul 1, 2014·Postgraduate Medicine·Richard S Castaldo
Dec 18, 2014·Cardiology and Therapy·Amir HassanAli Shaikh
Oct 11, 2015·Postgraduate Medicine·Anurag W Kedia, Erin Lynch
May 24, 2016·Canadian Pharmacists Journal : CPJ = Revue Des Pharmaciens Du Canada : RPC·Courtney P WalzSheri L Koshman
Aug 2, 2016·Clinical Medicine Insights. Cardiology·James R Crandell
Sep 30, 2016·Postgraduate Medicine·James R CrandellJoseph Tartaglia
Oct 18, 2016·Current Treatment Options in Cardiovascular Medicine·Kate J BowenPenny M Kris-Etherton
Feb 1, 2017·Lipids in Health and Disease·Eliot A Brinton, R Preston Mason
Mar 16, 2017·Circulation·David S SiscovickUNKNOWN American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiolo